<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028117</url>
  </required_header>
  <id_info>
    <org_study_id>ColoAd1-2001</org_study_id>
    <nct_id>NCT02028117</nct_id>
  </id_info>
  <brief_title>Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients</brief_title>
  <acronym>OCTAVE</acronym>
  <official_title>A Clinical Study Of Enadenotucirev: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PsiOxus Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PsiOxus Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I / Dose Expansion open label clinical study in patients with&#xD;
      platinum-resistant epithelial ovarian cancer. The Phase Ia part of the study will determine&#xD;
      the dose of enadenotucirev to be recommended for further studies and will examine primarily&#xD;
      the safety and tolerability but also the pharmacokinetics of administering enadenotucirev&#xD;
      intraperitoneally. In Phase Ib, the safety and tolerability and the pharmacokinetics of&#xD;
      administering enadenotucirev intravenously in combination with weekly paclitaxel will be&#xD;
      determined. The Dose Expansion Phase will begin as an open label dose expansion of that&#xD;
      regimen and aims to determine whether intravenous enadenotucirev in combination with weekly&#xD;
      paclitaxel has a risk benefit profile that supports further investigation in the treatment of&#xD;
      patients with platinum-resistant epithelial ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I - maximum tolerated dose</measure>
    <time_frame>Up to day 50 (post first dose)</time_frame>
    <description>The maximally-tolerated dose (MTD) and/or the dose of enadenotucirev recommended for further studies of enadenotucirev when administered as monotherapy by IP injection or as combination therapy by IV infusion with weekly paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Recurrent Platinum Resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Enadenotucirev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enadenotucirev</intervention_name>
    <description>Oncolytic Virus</description>
    <arm_group_label>Enadenotucirev</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide written informed consent and to comply with the study&#xD;
             protocol&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Histologically confirmed non-resectable epithelial ovarian, fallopian tube or primary&#xD;
             peritoneal cancer&#xD;
&#xD;
          4. Phase Ia and Phase Ib (first 3 patients):&#xD;
&#xD;
             Confirmed relapsed within the platinum-resistant time frame.&#xD;
&#xD;
               -  Platinum-resistance is defined as progression within 6 months of receiving prior&#xD;
                  platinum-containing chemotherapy, with progression identified either by CT&#xD;
                  scanning (RECIST v1.1) or symptomatic CA-125 progression (GCIG CA-125 criteria)&#xD;
&#xD;
               -  The treatment immediately prior to study entry need not be platinum-based OR&#xD;
                  Absence of other available treatment option&#xD;
&#xD;
             Phase Ib (after first 3 patients) and Dose Expansion Phase:&#xD;
&#xD;
             Confirmed relapsed within the platinum-resistant time frame&#xD;
&#xD;
               -  Platinum-resistance is defined as progression within 6 months of receiving prior&#xD;
                  platinum-containing chemotherapy, with progression identified either by CT&#xD;
                  scanning (RECIST v1.1) or symptomatic CA-125 progression (GCIG CA-125 criteria)&#xD;
&#xD;
               -  The treatment immediately prior to study entry need not be platinum-based&#xD;
&#xD;
             Phase Ia and Phase Ib (first 3 patients):&#xD;
&#xD;
             Evaluable disease (by RECIST v1.1).&#xD;
&#xD;
             Phase Ib (after first 3 patients) and Dose Expansion Phase:&#xD;
&#xD;
             Measurable disease (by RECIST v1.1)&#xD;
&#xD;
          5. Able to undergo IP injection, including all administration procedures e.g. placement&#xD;
             of IP catheter, iatrogenic ascites and ascites drainage and comply with study&#xD;
             procedures in the Investigator's opinion (only required for patients scheduled for IP&#xD;
             administration)&#xD;
&#xD;
          6. Recovered to at least grade 1 from the effects (excluding alopecia) of any prior&#xD;
             therapy for their malignancy at time of first administration of enadenotucirev&#xD;
&#xD;
          7. ECOG Performance Status Score of 0 - 1&#xD;
&#xD;
          8. Non-impaired renal function&#xD;
&#xD;
             • Creatinine ≤1.5 mg/dl and estimated glomerular filtration rate (eGFR) ≥60&#xD;
             mL/min/1.73m2 (or measured creatinine clearance ≥60 ml/min)&#xD;
&#xD;
          9. Urine dipstick for proteinuria at screening and baseline negative or trace. Patients&#xD;
             may be included with results of 1+ if they have a spot urinary albumin:creatinine&#xD;
             ratio (ACR) of either (i) ≤3 mg/mmol or (ii) &gt;3 mg - &lt;70 mg/mmol with a 24 hour&#xD;
             urinary protein &lt;0.2 g/24hours Adequate hepatic function&#xD;
&#xD;
               -  Serum bilirubin &lt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN&#xD;
&#xD;
         10. Adequate bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 x 109/l&#xD;
&#xD;
               -  Platelets ≥100 x 109/l&#xD;
&#xD;
               -  Haemoglobin ≥90 g/l&#xD;
&#xD;
         11. Adequate coagulation tests: INR ≤1.5 x ULN;&#xD;
&#xD;
         12. [Criterion has been removed in the current version of the protocol]&#xD;
&#xD;
         13. For females of childbearing potential, a negative pregnancy test must be documented&#xD;
             prior to enrolment&#xD;
&#xD;
         14. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile&#xD;
             (absence of ovaries and/or uterus): agreement to use two adequate methods of&#xD;
             contraception, including at least one method with a failure rate of &lt; 1% per year&#xD;
             (e.g. hormonal implants, combined oral contraceptives, vasectomised partner), during&#xD;
             the treatment period and for at least 3 months after the last dose of study drug&#xD;
&#xD;
         15. For selected patients in the Phase Ia and Dose Expansion Phase part of the study&#xD;
             participating in the exploratory assessment of tumour samples:&#xD;
&#xD;
             • Disease amenable to percutaneous image-guided biopsy.&#xD;
&#xD;
         16. Normal serum complement (C3/C4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria are not eligible for enrolment:&#xD;
&#xD;
          1. Tumours of malignant mixed mesodermal (MMMT) or mucinous subtypes, or non-epithelial&#xD;
             ovarian cancers (e.g. Brenner tumours, Sex-cord tumours)&#xD;
&#xD;
          2. [Criterion 2 has been removed in the current version of the protocol]&#xD;
&#xD;
          3. Symptomatic sub-acute bowel obstruction, characterised by e.g. regular bloating,&#xD;
             nausea, vomiting, constipation or diarrhoea&#xD;
&#xD;
          4. Pregnant or lactating (nursing) women&#xD;
&#xD;
          5. Known and/or a history or evidence of significant immunodeficiency due to underlying&#xD;
             illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome&#xD;
             [AIDS]) and/or medication (e.g. systemic corticosteroids at doses higher than&#xD;
             dexamethasone 20 mg [or other corticosteroid equivalent to dexamethasone dose] for 14&#xD;
             days or prolonged administration [&gt;14 days] of dexamethasone at doses higher than 10&#xD;
             mg but 20 mg [or other corticosteroid equivalent to dexamethasone dose] or other&#xD;
             immunosuppressive medications including cyclosporine, azathioprine, interferons,&#xD;
             within the past 14 days)&#xD;
&#xD;
          6. Complete splenectomy&#xD;
&#xD;
          7. Prior allogeneic or autologous bone marrow or organ transplantation&#xD;
&#xD;
          8. Active infections requiring antibiotics, physician monitoring, or recurrent fevers&#xD;
             &gt;38.0 degrees centigrade associated with a clinical diagnosis of active infection&#xD;
&#xD;
          9. Active viral disease, positive serology for HIV, hepatitis B or hepatitis C&#xD;
&#xD;
         10. Use of the following anti-viral agents:&#xD;
&#xD;
               -  Ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1&#xD;
&#xD;
               -  or pegylated interferon (PEG-IFN) (within 14 days prior to day 1)&#xD;
&#xD;
         11. Administration of an investigational drug within 28 days&#xD;
&#xD;
         12. Concurrent administration of any cancer therapy other than planned study treatment&#xD;
&#xD;
         13. Major surgery within 2 weeks prior to first dose of enadenotucirev&#xD;
&#xD;
         14. Phase Ib (after first 3 patients) and Dose Expansion Phase only: another primary&#xD;
             malignancy within the past 3 years (except for non-melanoma skin cancer or cervical&#xD;
             cancer in situ or in situ stage 1 synchronous endometrial cancer)&#xD;
&#xD;
         15. Symptomatic central nervous system (CNS) metastasis&#xD;
&#xD;
         16. Inflammatory diseases of the bowel&#xD;
&#xD;
         17. Concurrent congestive heart failure or prior history of New York Heart Association&#xD;
             (NYHA) class III/IV cardiac disease&#xD;
&#xD;
         18. Any condition or illness that, in the opinion of the Investigator or the medical&#xD;
             monitor, would compromise patient safety or interfere with the evaluation of the&#xD;
             safety of the drug&#xD;
&#xD;
         19. Known allergy to treatment medication or its excipients&#xD;
&#xD;
         20. Any other medical or psychological condition that would preclude participation in the&#xD;
             study or compromise ability to give informed consent.&#xD;
&#xD;
         21. Any history of renal disease or renal injury or autoimmune disease. Patients with&#xD;
             active, known or suspected auto-immune disease or a syndrome that requires systemic or&#xD;
             immunosuppressive agents; patients with vitiligo, type I diabetes mellitus, residual&#xD;
             hypothyroidism due to autoimmune disease only requiring hormone replacement, psoriasis&#xD;
             not requiring systemic treatment or conditions not expected to recur in the absence of&#xD;
             an external trigger are permitted to enrol providing they comply with the other&#xD;
             eligibility criteria relating to renal function)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clara Campal Comprehensive Cancer Center Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START MADRID-FJD, Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7WG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Institute</name>
      <address>
        <city>Glasgow</city>
        <zip>G61 1BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-001276-38/results</url>
    <description>OCTAVE results as listed on EudraCT</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 3, 2014</study_first_submitted>
  <study_first_submitted_qc>January 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2014</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

